Moving Beyond Accutane and Botox

Ever hungry for new investment opportunities, VCs are now backing start-ups developing novel dermatology products for both medical and cosmetic conditions. These aren't your typical "derm" companies. Not content to invent new delivery vectors for existing medicines or reformulate them into more patient friendly creams, these fledgling companies are trying to develop new chemical entities based on novel skin biology.

A few private investors are betting that dermatology may be the new ophthalmology. Just a few years ago that sector was viewed as a pharmaceutical backwater dogged by a diverse set of problems that included a fragmented market, drug delivery challenges, and less than effective therapies. But the advent of breakthrough therapeutics such as OSI Pharmaceuticals Inc. 's pegylated aptamer pegaptanib (Macugen) and Genentech Inc.'s antibody fragment ranibizumab (Lucentis), both for age related macular degeneration, has certainly changed the investment equation, and VCs and pharma alike have opened their eyes to money-making possibilities in ophthalmology. (See "Post Macugen, Still In-Licensing to Uncover Value in Ophthalmology," START-UP, July 2006 Also see "Post-Macugen, Still In-Licensing to Uncover Value in Ophthalmology" - Scrip, 1 July, 2006..)

Ever hungry for new investment opportunities, VCs from such leading firms as Versant Ventures, TVM Capital, MPM Capital, and Venrock...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

 

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

More from Business

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By 

The Swiss giant has been talking to the US government about selling medicines directly to patients.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.